Researchers found the French version of the drug, Norlevo, begins to lose effectiveness in women who weigh more than 165-pounds. And it's completely ineffective in women weighing over 176-pounds. Norlevo is identical to America's Plan B One-Step.
The Food and Drug Administration says it's reviewing the study and will determine if any labeling changes are warranted.
